1.08 is TG Therapeutics Inc’s (NASDAQ:TGTX) Institutional Investor Sentiment

Sentiment for TG Therapeutics Inc (NASDAQ:TGTX)

TG Therapeutics Inc (NASDAQ:TGTX) institutional sentiment decreased to 1.08 in 2019 Q1. Its down -0.11, from 1.19 in 2018Q4. The ratio dropped, as 42 hedge funds started new or increased stock positions, while 39 cut down and sold their equity positions in TG Therapeutics Inc. The hedge funds in our partner’s database now hold: 45.50 million shares, down from 47.33 million shares in 2018Q4. Also, the number of hedge funds holding TG Therapeutics Inc in their top 10 stock positions increased from 0 to 1 for an increase of 1. Sold All: 14 Reduced: 25 Increased: 28 New Position: 14.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $726.68 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

The stock increased 0.50% or $0.04 during the last trading session, reaching $8. About 939,602 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has declined 49.13% since July 14, 2018 and is downtrending. It has underperformed by 53.56% the S&P500.

Analysts await TG Therapeutics, Inc. (NASDAQ:TGTX) to report earnings on August, 6. They expect $-0.43 EPS, up 27.12 % or $0.16 from last year’s $-0.59 per share. After $-0.43 actual EPS reported by TG Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Opaleye Management Inc. holds 3.04% of its portfolio in TG Therapeutics, Inc. for 1.37 million shares. Ra Capital Management Llc owns 8.20 million shares or 2.84% of their US portfolio. Moreover, Bridger Management Llc has 2.55% invested in the company for 4.00 million shares. The France-based Credit Agricole S A has invested 0.57% in the stock. Highland Capital Management Lp, a Texas-based fund reported 878,360 shares.

Since January 1, 0001, it had 1 insider buy, and 0 selling transactions for $351,750 activity.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

Ratings analysis reveals 100% of TG Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating TG Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $15 while the high is $20. The stock’s average target of $17.50 is 118.75% above today’s ($8) share price. TGTX was included in 6 notes of analysts from February 21, 2019. As per Thursday, February 28, the company rating was maintained by H.C. Wainwright. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Tuesday, March 5 by SunTrust. The firm has “Buy” rating by H.C. Wainwright given on Thursday, June 20. H.C. Wainwright maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Thursday, February 21 with “Buy” rating. The company was maintained on Friday, March 8 by H.C. Wainwright.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Investorplace.com which released: “7 Stocks on Sale the Insiders Are Buying – Investorplace.com” on July 01, 2019, also Finance.Yahoo.com with their article: “Here’s What Hedge Funds Think About Fossil Group Inc (FOSL) – Yahoo Finance” published on June 18, 2019, Seekingalpha.com published: “TG Therapeutics up 17% premarket on positive umbralisib data – Seeking Alpha” on February 28, 2019. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: Nasdaq.com and their article: “Health Care Sector Update for 02/28/2019: TGTX, NVAX, RKDA – Nasdaq” published on February 28, 2019 as well as Seekingalpha.com‘s news article titled: “TG Therapeutics up 5% premarket on positive umbralisib data – Seeking Alpha” with publication date: April 01, 2019.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.